Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve Marginal Zone Lymphoma: A Study of Efficacy and Safety.

NCT07372365 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Soochow University as lead sponsor.

NCT NCT07372365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07372365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve Marginal Zone Lymphoma: A Study of Efficacy and Safety.
Lead sponsor
The First Affiliated Hospital of Soochow University
Phase
Phase 2
Overall status
Recruiting
Start date
October 24, 2025
Completion date
October 1, 2030
Enrollment
23 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marginal zone lymphoma (mzl)